Diagnostic Dilemma for Low Viremia with Significant Fibrosis; is Hepatitis B Virus DNA Threshold Level a Good Indicator for Predicting Liver Damage?
Diagnostic Dilemma for Low Viremia with Significant Fibrosis; is Hepatitis B Virus DNA Threshold Level a Good Indicator for Predicting Liver Damage?
Background: The most important difficulties about management ofhepatitis B are still determining the liver damage and the right time tostart antiviral therapy.Aims: To reveal the role of hepatitis B virus DNA threshold level forprediction of liver fibrosis and inflammation in young-aged hepatitisB e-antigen negative chronic hepatitis B patients.Study Design: Diagnostic accuracy study.Methods: A total of 273 hepatitis B e-antigen negative young chronichepatitis B patients with any hepatitis B virus DNA levels between2008 and 2016, who had liver biopsy after at least 6 months followup period, enrolled in this retrospective study. We created two groupsas case and control, cases with hepatitis B virus DNA levels below2000 IU/mL and controls with hepatitis B virus DNA levels over 2000IU/mL. Having histological activity index ≥4 or/and fibrosis scores≥2 were defined as significant histological abnormality. Then, weanalyzed the relationship between these groups.Results: We showed that significant fibrosis may occur in one third ofyoung chronic hepatitis B patients with low viremia (30.2%, n=42/139in cases, 55.2%, n=74/134 in controls). Among the 42 cases with lowviremia and significant fibrosis, 21.4% had alanine aminotransferaselevel between 40-59 U/L, 42.8% had alanine aminotransferase levelbetween 60-79 U/L, and 35.7% had alanine aminotransferase levelover 80 U/L. There was weak correlation between hepatitis B virusDNA threshold level and fibrosis score (p
___
- Shao J, Wei L, Wang H, Sun Y, Zhang LF, Li J, et al. Relationship between hepatitis
B virus DNA levels and liver histology in patients with chronic hepatitis B. World J
Gastroenterol 2007;13:2104-7.
- Ormeci A, Aydin Y, Sumnu A, Baran B, Soyer OM, Pinarbasi B, et al. Predictors
of treatment requirement in HBeAg-negative chronic hepatitis B patients with
persistently normal alanine aminotransferase and high serum HBV DNA levels. Int J
Infect Dis 2016;52:68-73.
- Chu CJ, Hussain M, Lok AS. Quantitative serum HBV DNA levels during different
stages of chronic hepatitis B infection. Hepatology 2002;36:1408-15.
- Abdo AA, Bzeizi KI, Babatin MA, AlSohaibani F, AlMana H, Alsaad KO, et al.
Predictors of significant fibrosis in chronic hepatitis B patients with low viremia. J
Clin Gastroenterol 2014;48:50-6.
- Sanai FM, Helmy A, Bzeizi KI, Babatin MA, Al-Qahtani A, Al-Ashgar HA, et al.
Discriminant value of serum HBV DNA levels as predictors of liver fibrosis in
chronic hepatitis B. J Viral Hepa 2011;18:217-25.
- Papatheodoridis GV, Manesis EK, Manolakopoulos S, Elefsiniotis IS, Goulis J,
Giannousis J, et al. Is there a meaningful serum hepatitis B virus DNA cutoff level
for therapeutic decisions in hepatitis B e antigen-negative chronic hepatitis B virus
infection? Hepatology 2008;48:1451-9.
- Sanai FM, Babatin MA, Bzeizi KI, Alsohaibani F, Al-Hamoudi W, Alsaad KO, et al.
Accuracy of international guidelines for identifying significant fibrosis in hepatitis
B e antigen--negative patients with chronic hepatitis. Clin Gastroenterol Hepatol
2013;11:1493-9.
- Barut S, Gemici Ü, Güneş F, Demir O, Duygu F. Predictors of histological indication
for treatment in HBeAg negative chronic HBV infection. J Med Virol 2017;89:1952-7.
- Nguyen LH, Chao D, Lim JK, Ayoub W, Nguyen MH. Histologic changes in liver
tissue from patients with chronic hepatitis B and minimal increases in levels of
alanine aminotransferase: a meta-analysis and systematic review. Clin Gastroenterol
Hepatol 2014;12:1262-6.
- Seto WK, Lai CL, Ip PP, Fung J, Wong DK, Yuen JC, et al. A large population histology
study showing the lack of association between ALT elevation and significant fibrosis
in chronic hepatitis B. PLoS One 2012;7:e32622.
- Papatheodoridis GV, Manolakopoulos S, Liaw YF, Lok A. Follow-up and indications
for liver biopsy in HBeAg-negative chronic hepatitis B virus infection with
persistently normal ALT: a systematic review. J Hepatol 2012;57:196-202.
- Charatcharoenwitthaya P, Phisalprapa P, Pausawasdi N, Rungkaew P, Kajornvuthidej
S, Bandidniyamanon W, et al. Alanine aminotransferase course, serum hepatitis B
virus DNA, and liver stiffness measurement for therapeutic decisions in hepatitis B e
antigen-negative chronic hepatitis B. Hepatol Res 2016;46:1347-57.
- Kao JH. Risk stratification of HBV infection in Asia-Pacific region. Clin Mol Hepatol
2014;20:223-7.
- Can A, Dogan E, Bayoglu IV, Tatli AM, Besiroglu M, Kocer M, et al. Multicenter
epidemiologic study on hepatocellular carcinoma in Turkey. Asian Pac J Cancer Prev
2014;15:2923-7.
- Bruden DJT, McMahon BJ, Townshend-Bulson L, Gounder P, Gove J, Plotnik J, et al.
Risk of end-stage liver disease, hepatocellular carcinoma, and liver-related death by
fibrosis stage in the hepatitis C Alaska Cohort. Hepatology 2017;66:37-45.
- Kumar M, Sarin SK, Hissar S, Pande C, Sakhuja P, Sharma BC, et al. Virologic and
histologic features of chronic hepatitis B virus-infected asymptomatic patients with
persistently normal ALT. Gastroenterology 2008;134:1376-84.
- Shafaei S, Soleimani Amiri S, Hajiahmadi M, Sadeghi-Haddad-Zavareh M, Bayani
M. Histological grading and staging of liver and its relation to viral loads in chronic
anti-HBe positive hepatitis. Caspian J Intern Med 2013;4:681-5.
- Eren M, Reyhanioglu S, Ciftci E, Dundar E, Us T, Dinleyici CE, et al. Correlation
of Liver Enzymes and Liver Histology in Chronic Hepatitis B Virus Infection. J Clin
Anal Med 2016;7:639-42.
- Guidelines for the Prevention, Care and Treatment of Persons with Chronic
Hepatitis B Infection. Geneva: World Health Organization; 2015 Mar.
WHO Guidelines Approved by the Guidelines Review Committee 2015.
- European Association for the Study of the Liver. Electronic address: easloffice@
easloffice.eu; European Association for the Study of the Liver. EASL 2017 Clinical
Practice Guidelines on the management of hepatitis B virus infection. J Hepatol
2017;67:370-98.
- Terrault NA, Bzowej NH, Chang KM, Hwang JP, Jonas MM, Murad MH, et al.
AASLD guidelines for treatment of chronic hepatitis B. Hepatology 2016;63:261-
83.
- Sarin SK, Kumar M, Lau GK, Abbas Z, Chan HL, Chen CJ, et al. Asian-Pacific
clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol
Int 2016;10:1-98.